Daratumumab: all 219 studies that test it
Page 3 of 3. Open to participants first (55), then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)WithdrawnNCT03221634Phase 2
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Phase 3
- A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without PomalidomideCompletedNCT03215524Phase 2
- Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)WithdrawnNCT03207542Phase 2
- MUK Nine b: OPTIMUM Treatment ProtocolActive, not recruitingNCT03188172Phase 2
- Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate CancerCompletedNCT03177460Phase 1
- Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory MyelomaStatus unknownNCT03143036Phase 2
- Neoadjuvant Listeria or Daratumumab in Prostate CancerWithdrawnNCT03035357Phase 2
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance TherapyActive, not recruitingNCT03004287Phase 2
- Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal ImpairmentCompletedNCT02977494Phase 2
- Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)Status unknownNCT02955810Phase 1
- A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell TransplantationCompletedNCT02918331Phase 1
- Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic TherapyCompletedNCT02852837Phase 1
- Daratumumab Therapy for Patients With Refractory or Relapsed AL AmyloidosisCompletedNCT02816476Phase 2
- Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple MyelomaCompletedNCT02626481Phase 2
- A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02497378Phase 1
- A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)CompletedNCT02431208Phase 1
- "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "CompletedNCT02419118Phase 2/3
- A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02116569Phase 1